This clinical trial tests the feasibility and efficacy of using text message reminders for completion of human papillomavirus (HPV) vaccination series in adolescent girls in Uganda. Sub-Saharan Africa has the highest cervical cancer mortality rates in the world and cervical cancer is the leading female cancer in Uganda. HPV is the principal cause of cervical cancer, making vaccination the single most important primary preventive measure. Text messages act as both a reminder for the needed doses as well as a vehicle for providing educational information about the vaccine. Using a text message reminder system may increase timeliness of HPV vaccination in adolescent girls in Uganda.
Additional locations may be listed on ClinicalTrials.gov for NCT05151367.
Locations matching your search criteria
United States
New York
New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterStatus: Active
Contact: Melissa S. Stockwell
Phone: 212-342-5732
PRIMARY OBJECTIVES:
I. To identify HPV vaccine text message reminder content (and parallel automated phone reminders) desired by the caregivers and their adolescent girls in Kampala.
II. To develop and pre-test HPV vaccine reminders with caregivers and their adolescent girls in Kampala.
III. Pilot assess the impact of vaccine reminders on HPV vaccination.
IV. Conduct a full-scale randomized-control trial to assess the impact of text message reminders on HPV vaccination.
OUTLINE:
R21 PHASE (FORMATIVE): Participants participate in formative interviews for the development of HPV vaccine reminder text messages on study.
R21 PHASE (DEVELOPMENT/PRE-TEST): Families evaluate the HPV vaccine reminder text message prototypes to provide feedback on clarity and persuasiveness on study.
R21 PHASE (PILOT)/R33 PHASE (FULL-SCALE): Families are randomized to 1 of 2 arms.
ARM I: Families receive text message HPV vaccine reminders and may participate in interviews on study.
ARM II: Families receive usual care and do not receive text message HPV vaccine reminders on study.
Trial PhaseNo phase specified
Trial Typeprevention
Lead OrganizationNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Principal InvestigatorMelissa S. Stockwell
